摘要
膀胱过度活动症（ OAB ）是一组以尿急症状为特征的症候群，严重影响患者的生活质量。琥珀酸索利那新为新一代毒蕈碱型乙酰胆碱受体（M受体）拮抗剂，对于膀胱逼尿肌具有高选择性，可明显缓解OAB患者尿急、尿失禁症状，增加其每次排尿量、减少其排尿次数；可改善输尿管支架植入术后患者的下尿路症状。M受体拮抗剂的主要不良反应为口干、认知功能损害和尿潴留。与奥昔布宁、托特罗定等M受体拮抗剂比较，琥珀酸索利那新的口干和尿潴留发生率低，对认知功能的影响小，但对于存在高危因素（如联用其他抗胆碱药、基础疾病造成血脑屏障通透性改变等）或既往有不同程度认知损害的老年患者则存在诱发或加重认知功能损害的风险。服用琥珀酸索利那新的第1个月应密切关注患者残余尿量的变化，以降低急性尿潴留的风险。
Overactive bladder is a group of syndromes characterized by symptoms of urinary urgency,seriously affecting the quality of life of patients. Solifenacin succinate is a new generation of muscarinic acetylcholine receptor（ M receptor）antagonist with high selectivity for detrusor,and it can not only obviously relieve the symptoms of urgency and incontinence,increase urination and reduce micturition frequency,but also improve lower urinary tract symptoms for patients after implantation of ureteral stents. The main adverse reactions of M receptor antagonist are dry mouth,cognitive impairment and urinary retention. Compared with oxybutynin and tolterodine,the incidences of dry mouth and urinary retention caused by solifenacin succinate are low,and it also has less effect on cognitive function. But for the patient with high risk factors（ such as combined use of other anticholinergic drugs and changes of blood brain barrier caused by primary diseases）and elderly patients with a history of cognitive impairment can induce or worsen the risk of cognitive impairment. During the first month of taking solifenacin succinate,more attention should be paid on the changes of residual urine volume in order to reduce the risk of acute urinary retention.
出处
《药物不良反应杂志》
CSCD
2015年第2期134-137,共4页
Adverse Drug Reactions Journal
